Management of Delirium
Introduction to Haloperidol Dosage
- The minimum effective dose of haloperidol for managing delirium is 0.5 mg, which should be administered orally or subcutaneously as needed, according to the Annals of Oncology guideline 1
- Starting dose: 0.5-1 mg orally (p.o.) or subcutaneously (s.c.) is recommended by the Annals of Oncology guideline 1
- For older or frail patients: Use lower doses of 0.25-0.5 mg and titrate gradually, as suggested by the Annals of Oncology guideline 1
- PRN (as needed) dosing: 0.5 or 1 mg p.o. or s.c. every 1 hour as needed, is recommended by the Annals of Oncology guideline 1
- Administer every 8-12 hours, according to the Annals of Oncology guideline 1
Alternative Medications
- Olanzapine: 2.5-5 mg p.o. or s.c. (may offer benefit in delirium management), as recommended by the Annals of Oncology guideline 1
- Quetiapine: 25 mg p.o. (less likely to cause EPSEs), is suggested by the Annals of Oncology guideline 1
- Aripiprazole: 5 mg p.o. or i.m. (less likely to cause EPSEs), according to the Annals of Oncology guideline 1
Contraindications and Precautions
- Contraindicated in Parkinson's disease or Lewy body dementia due to risk of EPSEs, as stated by the Annals of Oncology guideline 1
- May prolong QTc interval - ECG monitoring recommended for intravenous administration, according to the Annals of Oncology guideline 1
- Patients with hepatic impairment: Dose reduction required, as recommended by the Annals of Oncology guideline 1
- Elderly patients: Use 0.25-0.5 mg as starting dose, according to the Annals of Oncology guideline 1
Monitoring and Assessment
- Regular assessment of delirium severity using standardized tools is recommended 1
- Monitor for extrapyramidal symptoms, as suggested by the Annals of Oncology guideline 1
- ECG monitoring if using intravenous administration or if patient has cardiac risk factors, according to the Annals of Oncology guideline 1
- Assess for QTc prolongation, as recommended by the Annals of Oncology guideline 1
General Considerations
- Pharmacological interventions should be used only after addressing reversible precipitating factors of delirium, as delirium reversibility in palliative care units has been reported to be as high as 50% with appropriate management of underlying causes, according to the Annals of Oncology guideline 1